The results for pharmacological experiments of MT-141 were as follows; Twitch tension of gastrocnemius muscle evoked by the stimulation of sciatic nerve was slightly reduced with 400 mg/kg MT-141 i.v. and upper doses. As the change was very small, however, it seems that MT-141 has no neuromuscular junction blocking action. Although MT-141 did not show any effects on most of isolated smooth muscle organs, only isolated tracheal muscle was somewhat relaxed with 10(-3) g/ml MT-141. The spontaneous motility of smooth muscle in situ was temporarily increased with 800 mg/kg MT-141 i.v. and upper doses. Two hundred mg/kg MT-141 showed no effect on the value of blood sugar and functions of kidney and liver. Any hemolysis did not appear even in the highest dose of 200 mg/kg MT-141 used in this experiment. From the present results and previous report (Krebe, M. et al., Jap. J. Antibiotics, in press), it seems that MT-141 is promised to be a highly safe and useful antibiotic agent in clinical use.
Download full-text PDF |
Source |
---|
Acta Paediatr Jpn
February 1993
Department of Pediatrics, Mie University School of Medicine, Japan.
We reported a case of abscess in which Serratia marcescens was isolated as the causative organism. We measured the postantibiotic effect (PAE) of dibekacin (DKB) and gentamicin (GM) against S. marcescens and studied the relationship between the clinical effect and the PAE.
View Article and Find Full Text PDFJpn J Antibiot
October 1990
First Department of Surgery, School of Medicine, Nihon University.
Cefminox (CMNX), one of newly developed cephamycin antibiotics, was administered to 7 cases of diffuse peritonitis associated with infantile acute appendicitis to determine its concentrations in the blood, the appendiceal tissue and the purulent ascites and simultaneously to investigate its clinical efficacy. CMNX was intravenously injected at a dose of 20 mg/kg (at a maximum amount of 1.0 g/body) before operation and intravenously by bolus injection or by drip infusion twice daily after operation for 3 to 11 days in a total dose of 2.
View Article and Find Full Text PDFInt J Clin Pharmacol Res
August 1991
Pharmaceutical Division, Meiji Seika Kaisha, Tokyo, Japan.
In an open trial, 1841 patients were treated with mainly 1 g of cefminox twice a day in adults or 20-30 mg/kg three or four times a day in children for up to 14 days. The clinical efficacy was assessed in 1560 patients (1256 adults, 304 children) and the efficacy rates were as follows: 82.3% in respiratory tract infections (n:525), 85.
View Article and Find Full Text PDFAn appropriate choice of antibiotics plays an important role in the treatment of purulent peritonitis. We examined the pharmacokinetics and antimicrobial effect of cefminox (CMNX) on experimental purulent peritonitis made by intraperitoneal injection of E. coli and/or B.
View Article and Find Full Text PDFA new cephamycin antibiotic, cefminox (MT-141, CMNX), was intravenously infused into Beagle dogs at a dose of 40 mg/kg in order to study it's distribution to various tissues. The following results were obtained. The maximum serum concentration of CMNX observed at the end of the infusion period was 102.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!